Wagner Paul A. 4

What Happened Paul A. Wagner, CEO, Secretary and Chair of the Board of Forte Biosciences (FBRX), was granted 500,000 derivative shares on June 16, 2026. The reported acquisition price is $0.00 (a grant/award rather than an open-market purchase). This is an equity award subject to vesting rather than an immediate cash transaction or sale.

Key Details

• Transaction date: June 16, 2026; Form 4 filed June 17, 2026 (timely).
• Security: 500,000 derivative shares granted; acquisition price reported as $0.00.
• Vesting: 1/48th of the award vests monthly beginning June 16, 2026; fully vested after four years (June 16, 2030), contingent on continuing service.
• Shares owned after transaction: Not specified in the filing.
• Filing type/remark: Reported as an Award/Grant (code A); Wagner listed as CEO, Secretary and Chair.

Context This filing reflects an equity compensation award that vests over time (commonly RSUs or similar), not an open-market purchase or sale. Such awards are routine for executives and are contingent on continued service; they do not by themselves indicate immediate buying or selling of stock.